Results 81 to 90 of about 260,886 (316)
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
, 2017 Alessia E Russo,1 Domenico Priolo,1 Giovanna Antonelli,1 Massimo Libra,2 James A McCubrey,3 Francesco Ferraù1 1Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy; 2Laboratory of Translational Oncology & Functional ...
Antonelli G +17 more
core +1 more source
FEBS Open Bio, EarlyView.In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes +32 more
wiley +1 more source
Screening and diagnosis of NSCLC
Annals of Oncology, 2004 Lung cancer is the biggest cancer killer in Europe. Non-small-cell lung cancer (NSCLC) accounts for the vast majority ofcases. The annual number of newly diagnosed patients inEurope exceeds 200000, accounting for 20% of all cancerdeaths, and on average 28% of male cancer deaths across thecontinent [1, 2].
Van Meerbeeck, Jan, Tournoy, Kurt
openaire +3 more sources
Aging and Cancer, EarlyView.This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel +4 more
wiley +1 more source
Open Life Sciences, 2016 Lung cancer is the leading cause of cancer-related death, with non-small cell lung cancer (NSCLC) accounting for more than 80% of all lung cancer cases.
Yunxia Zhang, Hongying Dong
doaj +1 more source
The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer [PDF]
, 2022 INTRODUCTION: Carboplatin is an anticancer drug used for treatment of various types of cancer including non-small cell lung cancer (NSCLC). Dosing is based on estimated glomerular filtration rate (GFR) using the Cockcroft-Gault formula.
Santeon NSCLC Study Group
core
Outcomes of patients with EGFR-mutant advanced NSCLC in a developing country in Southeast Asia
, 2022 Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR T790M mutation.
Yong, Kek Pang +16 more
core +1 more source
Advanced Healthcare Materials, EarlyView.A miniaturized drug sensitivity and resistance testing (DSRT) workflow based on the Droplet Microarray (DMA) platform enables functional drug testing using minimal patient‐derived tumor material. By screening nanoliter‐scale droplets containing as few as 300 cells, this approach generates reproducible and tumor‐specific drug response profiles ...
Maryam Salarian +7 more
wiley +1 more source
The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma
OncoImmunology, 2018 Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3.
Katerina Kachler +4 more
doaj +1 more source
Advanced Robotics Research, EarlyView.An AI‐powered, robot‐assisted framework automatically produces, images, and analyzes 3D tumor spheroids to evaluate drug efficacy. Integrated modules handle spheroid formation, live/dead staining, brightfield imaging, and automated image analysis, including spheroid segmentation, viability and metrics to assess the drug treatment efficacy. The workflow
Dalia Mahdy +13 more
wiley +1 more source